论文信息 - Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce.

Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce.

Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce A 2-dose regimen of the BNT162b2 vaccine (Pfizer-BioNTech) against SARS-CoV-2 was authorized in December 2020 based on reported 94.8% efficacy.1 Although an association between vaccination and a reduction in symptomatic disease has been well described, an association with asymptomatic infection remains unclear.2,3

[1] M. Hernán,et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting , 2021, The New England journal of medicine.

[2] Y. Kreiss,et al. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients , 2021, The Lancet.

[3] Ping Li,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020 .

[4] S. M. Martin,et al. Recommendations for the use of Taylor series confidence intervals for estimates of vaccine efficacy. , 1988, Bulletin of the World Health Organization.